Compare SIRI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIRI | ORKA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 7.1B |
| IPO Year | 1996 | 1997 |
| Metric | SIRI | ORKA |
|---|---|---|
| Price | $25.93 | $84.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $28.86 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 3.8M | 809.6K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 136.32 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $5,425,129,000.00 | N/A |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $0.67 | N/A |
| P/E Ratio | $18.75 | ★ N/A |
| Revenue Growth | ★ 8.13 | N/A |
| 52 Week Low | $19.77 | $15.80 |
| 52 Week High | $32.66 | $115.52 |
| Indicator | SIRI | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 36.00 |
| Support Level | $25.30 | $83.25 |
| Resistance Level | $30.13 | $97.45 |
| Average True Range (ATR) | 0.77 | 5.07 |
| MACD | -0.28 | -0.85 |
| Stochastic Oscillator | 8.94 | 15.29 |
Sirius XM operates almost exclusively in the US through its SiriusXM and Pandora audio services. SiriusXM is primarily a satellite radio service that offers nationwide coverage and mostly ad-free listening, with proprietary channels and exclusive content. It makes agreements with automakers to install its radios in vehicles and give trial services to vehicle buyers, which have traditionally fed its subscriber base. The company provides the service via a fleet of geostationary satellites it owns and operates and now offers a streaming SiriusXM option. Pandora, which accounts for a much smaller portion of revenue and profit, offers a subscription and ad-supported streaming music service that competes with industry giants such as Spotify, Apple Music, and YouTube Music.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.